Lexicon Pharmaceuticals stock reaches a key HCM milestone

Published on 09/29/2026 at 19:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lexicon Pharmaceuticals stock gains a clinical milestone as SONATA-HCM enrollment exceeds 500 patients. Cantor Fitzgerald set an USD 8.00 target on September 28, 2026.

LXRX, US5396941031, Illustration mit AI erstellt.

Lexicon Pharmaceuticals stock reached a key clinical milestone after the company completed enrollment in its Phase 3 SONATA-HCM study with more than 500 patients. MarketBeat reported on September 20, 2026 that topline data are expected in the first quarter of 2027.

HCM trial moves ahead

SONATA-HCM is evaluating sotagliflozin in obstructive and non-obstructive hypertrophic cardiomyopathy. The study was designed for 500 patients but exceeded that target, and its 26-week design uses the Kansas City Cardiomyopathy Questionnaire as a primary assessment.

The enrollment update gives Lexicon a defined clinical checkpoint, but the financial base remains narrow. For the second quarter of 2026, MarketBeat reported revenue of USD 0.69 million against a USD 3.99 million consensus estimate. The company posted an EPS loss of USD 0.06 versus a consensus loss of USD 0.05, a USD 0.01 miss.

Analyst target sets a test

Investing.com reported on September 28, 2026 that Cantor Fitzgerald initiated coverage with an Overweight rating and an USD 8.00 price target. The analyst view centers on sotagliflozin's potential in HCM and the possibility that the drug could complement existing cardiac myosin inhibitor therapies.

The target sits alongside a more cautious consensus picture. MarketBeat cited an average Hold rating and an average target of USD 5.70 from five analysts. That spread makes the upcoming trial data the central valuation test rather than the latest quarterly revenue.

Market value and next dates

Lexicon's market capitalization was USD 810.7 million on September 29, 2026, while its 52-week range was USD 1.10 to USD 2.68. Yahoo Finance listed November 5, 2026 as the next earnings date.

Lexicon also plans to resubmit its sotagliflozin application for type 1 diabetes in the fourth quarter of 2026, while the SONATA-HCM readout is expected in the first quarter of 2027. Those dates give the stock two distinct clinical and regulatory checkpoints.